{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 49,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The diagram illustrates a dose escalation study design with three cohorts leading to the RP2D.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/26",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.49,
        "x": 0.13,
        "y": 0.43
      },
      "kind": "diagram",
      "text": "Dose escalation steps from 150x10^6 to 800x10^6",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e3da4c5-8ae7-4ee6-95b1-a583a3542b67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.67,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "RP2D already determined at at 800x10^6. 50 patients in MM. 8 in AL. Dosing ongoing...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "923a45c7-4c6a-4e39-abbf-24a7cd1af482",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.7,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: 8 patients treated in relapsed/refractory AL amyloidosis as of May 11, 2023, 5 at 800 x10^6 cells, 2 at 250 x10^6 cells, 1 at 150x10^6 cells. Multiple Myeloma data cutoff at February 9th, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79e2e934-9942-4f15-a4ea-4ecf9166ce66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.02,
        "y": 0.1
      },
      "kind": "title",
      "text": "Recommended Phase 2 Dose (RP2D) Already Determined at 800x10^6",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e15d994f-c55f-47d7-a079-bbf61bcaaadf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Ongoing Clinical Study Design (NEXICART-1/NCT04720313) in Multiple Myeloma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50882bea-d384-4b66-9a9d-59c220b25241",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "dose-escalation-study",
      "slug": null,
      "matchId": "418e34dc-e6e2-4f2d-9514-7e212d8e1a36",
      "evidence": "Visual representation of clinical trial cohort progression",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 22,
      "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Discussion of market opportunity and clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 22,
      "name": "Pareto Focus",
      "slug": "50-pareto-focus",
      "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
      "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
      "evidence": "Presentation of market data and clinical development plan",
      "position": 1,
      "objective": "Focusing on key markets and opportunities",
      "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
      "confidence": 0.7,
      "description": "Show that 80% of results come from 20% of causes to drive prioritization"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}